Evommune, Inc. (EVMN) Stock Statistics & Valuation Metrics

Evommune, Inc. has a market cap or net worth of $531.68M. The enterprise value is $288.08.

Evommune, Inc. has 36,292,114 shares outstanding. The number of shares has decreased by -2.65% in one year.

Evommune, Inc.’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -39.05%.

The current PE Ratio of Evommune, Inc. is ―. Evommune, Inc.’s PEG ratio is 1.98.

In the last 12 months, Evommune, Inc. had revenue of 13.00M and earned -68.87M in profits. Earnings per share was -2.18.

In the last 12 months, operating cash flow was -74.15M and capital expenditures -501.00K, giving a free cash flow of -74.65M billion.

Evommune, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Evommune, Inc. upcoming earnings date is Dec 10, 2026, After Close (Confirmed).

Evommune, Inc. as a current ratio of 8.57, with Debt / Equity ratio of 2.92%

In the past 12 months, Evommune, Inc. has paid 0.00 in taxes.

Evommune, Inc. EV to EBITDA ratio is -7.38, with an EV/FCF ratio of -6.49.

Evommune, Inc. has $200.79M in cash and marketable securities with $8.11M in debt, giving a net cash position of $192.68M billion.

Gross margin is 96.51%, with operating margin of -623.62%, and net profit margin of -529.77%.

The average price target for Evommune, Inc. is $27.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy